Cigna's revenue growth accelerated to 6.6% in Q2 2026, driven by Evernorth's pharmacy volumes, while the combined ratio remained stable near 96.3%. However, the loss ratio swung from 90.6% to 79.1% quarter-over-quarter, suggesting reserve releases may be masking underlying cost inflation.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 6.6% in Q2 2026, but the loss ratio swung from 90.6% to 79.1%, indicating reserve releases may be supporting earnings.
Cigna has consistently outperformed analyst expectations, with EPS surpassing forecasts and revenue growth exceeding consensus estimates. The company’s earnings quality is further supported by its disciplined cost control approach. This trend positions Cigna for continued profitability.
Cigna maintains resilient free cash flow, bolstered by modest leverage levels. The company’s disciplined cost control approach ensures cash generation remains strong. This financial strength provides flexibility for future growth initiatives.
Cigna’s Pharmacy Benefit Management (PBM) business has transitioned to a fee-based model, structurally de-risking the segment. The company has secured extended contracts with its largest PBM customers, enhancing long-term visibility. This shift supports sustainable revenue growth.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $7.98+6.1% vs $7.52 | $73.7B+1.4% vs $72.6B |
Q3 2026 Jul 30, 2026 | $7.78+2.4% vs $7.60 | $71.7B+2.2% vs $70.1B |
Q2 2026 Apr 30, 2026 | $7.79+2.5% vs $7.60 | $68.5B+3.3% vs $66.3B |
Q1 2026 Feb 5, 2026 | $8.08+2.5% vs $7.88 | $72.5B+3.1% vs $70.3B |
Cigna Group NYSE: CI raised its full-year adjusted earnings outlook after reporting $73.8 billion in adjusted revenue and $2.1 billion in adjusted after-tax earnings for the third quarter of 2026.
Cigna Group maintains a Buy rating, supported by robust earnings, raised guidance, and a sector-discounted valuation despite PBM margin pressures. CI raised 2026 adjusted EPS guidance to at least $30.60, with management targeting 10% adjusted EPS growth in 2027 from a normalized $30 base. Healthcare segment margins improved, while PBM faces headwinds from contract renewals, rebate compression, and regulatory risks, but contract wins and retention remain strong.
Cigna Group (NYSE: CI - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $318.05 and last traded at $312.8470, with a volume of 257,944 shares changing hands. The stock had previously closed at $305.41. The health
The Cigna Group ( CI ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Ralph Giacobbe - Senior Vice President of Investor Relations Brian Evanko - President, CEO & Director Ann Dennison - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Kevin Fischbeck - BofA Securities, Research Division Albert Rice - UBS Investment Bank, Research Division Justin Lake - Wolfe Research, LLC Scott Fidel - Goldman Sachs Group, Inc., Research Division Jason Cassorla - Guggenheim Securities, LLC, Research Division Charles Rhyee - TD Cowen, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Dean Rosales - Leerink Partners LLC, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by for The Cigna Group's Third Quarter 2026 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
Benchmark CI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cigna Corporation (CI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $293.59 | $77.66B | 13.24 | 11.26% | 2.17% | 14.33% | 2.06% | |
| $394.15 | $357.95B | 29.79 | 11.81% | 3.53% | 15.18% | 2.21% | |
| $425.62 | $92.3B | 16.94 | 12.62% | 2.55% | 11.56% | 1.62% | |
| $83.85 | $106.99B | 60.32 | 7.85% | 1.18% | 6.41% | 3.19% | |
| $433.74 | $52.08B | 44.08 | 10.06% | 0.88% | 6.89% | 0.82% | |
| $69.70 | $34.43B | -5.12 | 19.44% | 0.75% | 6.76% | — |
Cigna Corporation (CI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cigna Corporation (CI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 13, 2026·SEC
Apr 30, 2026·SEC
Get notified when CI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cigna Corporation (CI) stock FAQ — growth, dividends, profitability & financials explained
Cigna Corporation (CI) grew revenue by 11.3% in fiscal year 2025, compared with the prior fiscal year.
Yes. Cigna Corporation (CI) earned $6.42B in net income over the trailing twelve months (a 2.3% net margin).
Yes. Cigna Corporation (CI) pays a dividend that yields 2.06% at the current price, a moderate yield.
Cigna Corporation (CI) had a return on equity (ROE) of 14.3% in fiscal year 2025. That is in line with the market's typical 10-15%.
Cigna Corporation (CI) has a combined ratio of 96.7%. A ratio below 100% indicates underwriting profitability.
